. Author manuscript; available in PMC: 2009 Dec 3.

Published in final edited form as: Eur J Pharmacol. 2008 Oct 9;599(1-3):36–43. doi: 10.1016/j.ejphar.2008.09.043

Table 2.

Potency and maximal effect data for cAMP inhibition experiments. For each condition of rpMOR or hMOR treatment with morphine or DAMGO, the maximum percent inhibition (I_max) is shown as the greatest percent of inhibition of [³H]-cAMP accumulation elicited by opioid agonist in forskolin-stimulated cells. In addition, the potency of inhibition (IC₅₀) is noted for each condition. Both parameters were predicted by a best-fit to a one-site competition curve using GraphPad Prism software (v. 4.0).

rpMOR	IC₅₀ (nM)	S.E.M. (nM)	I_max (%)	S.E.M. (nM)	hMOR	IC₅₀ (nM)	S.E.M. (nM)	I_max (%)	S.E.M. (nM)	IC₅₀ Ratio^a	I_max Ratio^b
*Agonists*					*Agonists*
Morphine	73.9	± 49.0	48.2	± 2.49	Morphine	42.1	± 4.26	84.4	± 1.13	0.6	0.3^#
DAMGO	101	± 65.2	74.7	± 4.30	DAMGO	7.42	± 1.67	88.8	± 2.37	0.07^#	0.4^#

The ratios of the IC₅₀^a and I_max^b values for rpMOR over those for hMOR were determined and ^#annotated where p<0.05 (unpaired, two-tailed Student's t-test).